| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:900.)
© 2002 American Heart Association, Inc.
Clinician Update |
From the Division of Cardiac Surgery (P.W.M.F., S.V., T.E.D., R.D.W.) and Department of Pathology (R.L.L., J.B.), University of Toronto, Toronto General Hospital, Toronto, Ontario, Canada.
Correspondence to Jagdish Butany, MBBS, MS, FRCPC, Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto, Department of Pathology, Toronto General Hospital, E4-322, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4. E-mail jagdish.butany{at}uhn.on.ca
| Introduction |
|---|
|
|
|---|
The bicuspid aortic valve (BAV) is the most common congenital cardiac malformation, occurring in 1% to 2% of the population. The majority of BAV patients develop complications requiring treatment. Physicians are often challenged when asked to provide evidence-based advice about BAV disease because the pathogenesis and pathophysiology of this disease are not well understood.
| What Causes Bicuspid Aortic Valves? |
|---|
|
|
|---|
|
The pathogenesis of congenital aortic valve malformations is unknown. Proponents of environmental causes believe that abnormal blood flow through the aortic valve during valvulogenesis results in a failure of cusp separation. However, there is no convincing evidence to support this claim. A genetic cause of BAV disease is perhaps a more substantiated explanation, although it is not conclusive. In support of a genetic cause, BAV is highly associated with congenital abnormalities of the aorta (coarctation of the aorta and patent ductus arteriosis) and the proximal coronary vasculature. After development, BAV is associated with aortic dilation, aneurysms, and dissection (Figure 2). In light of this, the BAVs should be considered a disease of the entire aortic root.
|
The extracellular matrix (ECM) plays an important role in providing both structural support as well the environmental cues necessary for normal tissue development and homeostasis. In fact, ECM proteins help to direct cell differentiation and cusp formation during valvulogenesis. Microfibrillar proteins act as scaffolding for embryonic cells and regulate tissue formation in the developing aortic valves. In fact, the differentiation of cushion mesenchymal cells into mature valve cells correlates with the expression of the microfibrillar proteins fibrillin and fibulin.2 Microfibrillar proteins within the aortic matrix may be deficient in patients with BAV. Inadequate production of fibrillin-1 during valvulogenesis may disrupt the formation of the aortic cusps, resulting in a bicuspid valve and a weakened aortic root. Our preliminary data support the hypothesis that microfibrillar proteins are deficient in adults with BAV disease, disrupting the structural support of the aortic root.
Defects in the genes that encode matrix elements have not yet been identified in patients with BAVs. Although the gene for fibrillin-1 may be structurally normal, transcriptional elements that control protein production may be defective. Transcriptional elements are emerging as important mediators of many other congenital cardiac defects.3 Abnormalities of the gene encoding endothelial nitric oxide synthase (eNOS) is also an important candidate, because mice with eNOS deficiency have a high incidence of congenital BAV.4 Although a single "BAV gene" has yet to be identified, there is likely a heterogeneous mechanism of causation resulting in diverse clinical phenotypes. Advances in molecular biology will most certainly uncover the molecular and cellular mediators involved in this common disorder.
| Are BAVs Hereditary? |
|---|
|
|
|---|
| What Are the Risks of BAV? |
|---|
|
|
|---|
33% of patients with BAV, the bicuspid valve may be responsible for more deaths and morbidity than the combined effects of all the other congenital heart defects.7 Although patients with BAV may go undetected or without clinical consequences for a lifetime, the vast majority will require some intervention, most often surgery. The important clinical consequences of BAV disease are valvular stenosis, regurgitation, infective endocarditis, and aortic complications such as dilation and dissection, as shown in the Table.
|
| Valvular Complications |
|---|
|
|
|---|
|
Aortic regurgitation occurs in the presence of a BAV usually from cusp prolapse, fibrotic retraction, or dilation of the sinotubular junction. Isolated regurgitation usually occurs in younger patients,9 as in the case presented above, and may reflect a subset of patients more prone to aortic complications. Endocarditis is a potentially devastating complication that occurs in
30% of patients with BAV, particularly with regurgitant valves and in younger patients.
| Vascular Complications |
|---|
|
|
|---|
50% of young patients with normally functioning BAVs have echocardiographic evidence of aortic dilation.11 Aortic dilation is believed to be a precursor to aortic rupture and dissection, both potentially fatal events. BAV is associated with accelerated degeneration of the aortic media, indicating that BAV disease is an ongoing pathological process, not a discrete developmental event. We and others1216 have identified focal abnormalities within the aortic media of patients with BAV, such as matrix disruption and smooth muscle cell loss, suggesting a degenerative process that may result in structural weakness of the aortic wall. These lesions are similar in fibrillin-1deficient aorta17,18 and patients with Marfan Syndrome,16 who also suffer from abnormal fibrillin-1 content. A loss of fibrillin-1 microfibrils may dissociate smooth muscle cells from medial matrix components, resulting in accelerated cell death and matrix disruption (Figure 4). Matrix metalloproteinases (MMPs), endogenous enzymes that degrade matrix components, have been implicated in atherosclerotic aortic aneurysm formation.19 MMPs become activated in fibrillin-1deficient tissues,17,18,20 degrading the structural support of the aorta and resulting in dilation, aneurysms, and dissection. Our preliminary data suggest that MMP activity may be elevated in the aorta of patients with BAV. Understanding the pathophysiology of the aortic complications associated with BAV may facilitate the discovery of underlying gene defects and possible therapeutic targets and strategies to prevent these life-threatening complications.
|
| How Should BAV Disease Be Treated? |
|---|
|
|
|---|
In general, patients with mild-to-moderate valvular dysfunction and normal left ventricular (LV) dimensions and function should be monitored by echocardiography at regular intervals. Aortic valve replacement is indicated for severe valvular dysfunction, symptomatic patients, and/or those patients with evidence of abnormal LV dimensions and function (Table). Because many of these patients will require cardiac surgery during their lifetime, early referral to a surgeon with experience in aortic valve surgery is recommended. Patients with isolated aortic regurgitation may be candidates for aortic valve repair, an intervention that obviates the need for long-term anticoagulation.22 Early referral before significant deterioration of the cusps may increase the chance for a successful valve repair. Use of the pulmonary autograft (Ross procedure) for aortic valve replacement has been advocated as an important alternative to prosthetic valve implantation, particularly in younger patients. Underlying medial abnormalities in patients with BAV may predispose to postoperative autograft dilatation23 because the pulmonary artery has the same embryological origin as the aorta and undergoes similar degenerative changes13 (Figure 5).
|
Aortic dilation should be carefully monitored by echocardiography21 and aortic root replacement recommended more aggressively for patients with BAV24 with aortic dilation (ie, 4 to 5 cm) than for those of patients with tricuspid valve (ie, 5 to 6 cm). Combined aortic valve repair with a valve-sparing root replacement can be performed successfully in young patients with aortic regurgitation and aortic dilation. The benefit of ß-blockers to prevent aortic dilation in BAV disease is not clear; however, hypertension should be carefully monitored and controlled. The role of MMP inhibitors and gene or protein therapy to augment deficient extracellular matrix components in the bicuspid aorta is an exciting prospect that warrants further investigation.
| Conclusions |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
G. B. Pettersson, A. C. Crucean, R. Savage, C. M. Halley, R. A. Grimm, L. G. Svensson, S. Naficy, A. M. Gillinov, J. Feng, and E. H. Blackstone Toward predictable repair of regurgitant aortic valves a systematic morphology-directed approach to bicommissural repair. J. Am. Coll. Cardiol., July 1, 2008; 52(1): 40 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Borer and L. N. Girardi Repair of the congenitally bicuspid regurgitant aortic valve a strategic advance. J. Am. Coll. Cardiol., July 1, 2008; 52(1): 50 - 51. [Full Text] [PDF] |
||||
![]() |
Z. Touat, L. Lepage, V. Ollivier, P. Nataf, U. Hvass, J. Labreuche, M. Jandrot-Perrus, J.-B. Michel, and G. Jondeau Dilation-Dependent Activation of Platelets and Prothrombin in Human Thoracic Ascending Aortic Aneurysm Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 940 - 946. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Fazel, H. R. Mallidi, R. S. Lee, M. P. Sheehan, D. Liang, D. Fleischman, R. Herfkens, R. S. Mitchell, and D. C. Miller The aortopathy of bicuspid aortic valve disease has distinctive patterns and usually involves the transverse aortic arch. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 901 - 907.e2. [Abstract] [Full Text] [PDF] |
||||
![]() |
M J Collins, J Butany, M A Borger, B H Strauss, and T E David Implications of a congenitally abnormal valve: a study of 1025 consecutively excised aortic valves J. Clin. Pathol., April 1, 2008; 61(4): 530 - 536. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Bedard, D. F. Shore, and M. A. Gatzoulis Adult congenital heart disease: a 2008 overview Br. Med. Bull., March 1, 2008; 85(1): 151 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Khan, A. B. Sallehuddin, Z. R. Al-Bulbul, and Z. Y. Al-Halees Neoaortic Bicuspid Valve in Arterial Switch Operation: Mid-Term Follow-Up Ann. Thorac. Surg., January 1, 2008; 85(1): 179 - 184. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Padera Jr. and F. J. Schoen Pathology of Cardiac Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 111 - 178. [Full Text] |
||||
![]() |
T. Mihaljevic, M. R. Sayeed, S. C. Stamou, and S. Paul Pathophysiology of Aortic Valve Disease Card. Surg. Adult, January 1, 2008; 3(2008): 825 - 840. [Full Text] |
||||
![]() |
L Stefani, G Galanti, L Toncelli, P Manetti, M C Vono, M Rizzo, and N Maffulli Bicuspid aortic valve in competitive athletes Br. J. Sports Med., January 1, 2008; 42(1): 31 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Jones, R. E. Stroud, B. S. Kaplan, A. M. Leone, J. E. Bavaria, J. H. Gorman III, R. C. Gorman, and J. S. Ikonomidis Differential Protein Kinase C Isoform Abundance in Ascending Aortic Aneurysms From Patients With Bicuspid Versus Tricuspid Aortic Valves Circulation, September 11, 2007; 116(11_suppl): I-144 - I-149. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Matt, A. von Orelli, F. Bernet, T. Grussenmeyer, I. Lefkovits, and H.-R. Zerkowski Proteomics of Ascending Aortic Aneurysm with Bicuspid or Tricuspid Aortic Valve Asian Cardiovasc Thorac Ann, June 1, 2007; 15(3): 185 - 190. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-H. Sievers and C. Schmidtke A classification system for the bicuspid aortic valve from 304 surgical specimens J. Thorac. Cardiovasc. Surg., May 1, 2007; 133(5): 1226 - 1233. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. B. Grotenhuis, J. Ottenkamp, J. J.M. Westenberg, J. J. Bax, L. J.M. Kroft, and A. de Roos Reduced aortic elasticity and dilatation are associated with aortic regurgitation and left ventricular hypertrophy in nonstenotic bicuspid aortic valve patients. J. Am. Coll. Cardiol., April 17, 2007; 49(15): 1660 - 1665. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Davies, R. K. Kaple, D. Mandapati, A. Gallo, D. M. Botta Jr, J. A. Elefteriades, and M. A. Coady Natural History of Ascending Aortic Aneurysms in the Setting of an Unreplaced Bicuspid Aortic Valve Ann. Thorac. Surg., April 1, 2007; 83(4): 1338 - 1344. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Della Corte, C. Bancone, C. Quarto, G. Dialetto, F. E. Covino, M. Scardone, G. Caianiello, and M. Cotrufo Predictors of ascending aortic dilatation with bicuspid aortic valve: a wide spectrum of disease expression Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 397 - 405. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Walker, D. H.L. Bail, M. Gruler, R. Vonthein, V. Steger, and G. Ziemer Unsupported Reduction Ascending Aortoplasty: Fate of Diameter and of Windkessel Function Ann. Thorac. Surg., March 1, 2007; 83(3): 1047 - 1053. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gerosa, S. Pontarollo, S. Iliceto, and F. di Marco An alternative technique for aortic root remodeling in patients with bicuspid aortic valve J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 249 - 250. [Full Text] [PDF] |
||||
![]() |
J. Aboulhosn and J. S. Child Left Ventricular Outflow Obstruction: Subaortic Stenosis, Bicuspid Aortic Valve, Supravalvar Aortic Stenosis, and Coarctation of the Aorta Circulation, November 28, 2006; 114(22): 2412 - 2422. [Full Text] [PDF] |
||||
![]() |
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF] |
||||
![]() |
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): 598 - 675. [Full Text] [PDF] |
||||
![]() |
G. El Khoury, J.-L. Vanoverschelde, D. Glineur, F. Pierard, R. R. Verhelst, J. Rubay, J.-C. Funken, C. Watremez, P. Astarci, V. Lacroix, et al. Repair of Bicuspid Aortic Valves in Patients With Aortic Regurgitation Circulation, July 4, 2006; 114(1_suppl): I-610 - I-616. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Otto Valvular Aortic Stenosis: Disease Severity and Timing of Intervention J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2141 - 2151. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Kirsch, N C. Radu, E. Allaire, and D. Y Loisance Pathobiology of Idiopathic Ascending Aortic Aneurysms Asian Cardiovasc Thorac Ann, June 1, 2006; 14(3): 254 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Majumdar, M. Yagubyan, G. Sarkar, M. E. Bolander, and T. M. Sundt III Bicuspid aortic valve and ascending aortic aneurysm are not associated with germline or somatic homeobox NKX2-5 gene polymorphism in 19 patients J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1301 - 1305. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Verma, P. E. Szmitko, P. W. M. Fedak, L. Errett, D. A. Latter, and T. E. David Can statin therapy alter the natural history of bicuspid aortic valves? Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2547 - H2549. [Full Text] [PDF] |
||||
![]() |
P. J. Nash, E. Vitvitsky, J. Li, D. M. Cosgrove III, G. Pettersson, and R. A. Grimm Feasibility of Valve Repair for Regurgitant Bicuspid Aortic Valves--An Echocardiographic Study Ann. Thorac. Surg., May 1, 2005; 79(5): 1473 - 1479. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Lewin and C. M. Otto The Bicuspid Aortic Valve: Adverse Outcomes From Infancy to Old Age Circulation, February 22, 2005; 111(7): 832 - 834. |